DNA-based tumor vaccines

Onkologie

Volumn 25, Issue 6, 2002, Pages 528-532

  Pecher, Gabriele ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antigen; DNA; Tumor; Vaccine

Indexed keywords

CANARY POX RECOMBINANT VACCINE; DNA BASE; EPITOPE; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; NONHUMAN; REVIEW; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; EPITOPES; HUMANS; NEOPLASMS; VACCINES, DNA;

EID: 0036986210     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068623     Document Type: Review

References (60)

1. Renkvist N, Castelli C, Robbins PE, Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
2. Chen W, Anton LC, Bennink JR, Yewdell JW: Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000;12:83-93.
3. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM: Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 2001;166:5366-5373.
4. Wang RE, Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol Rev 1999;170:85-100.
5. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-151.
6. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
7. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, deCock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Otten-hoff TH, Offringa R, Melief CJ: Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 1998;58:724-731.
8. Gong J, Chen D, Kashiwaba M, Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-561.
9. Banchereau J, Steinman, RM: Dendritic cells and the control of immunity. Nature 1998;392:245-252.
10. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ: Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 1996;56:3763-3770.
11. Aicher A, Westermann J, Cayeux S, Willimsky G, Daemen K, Blankenstein T, Uckert W, Dorken B, Pezzutto A: Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene-modified antigen presenting cells. Exp Hematol 1997;25:39-44.
12. Szabolcs P, Gallardo HF, Ciocon DH, Sadelain M, Young JW: Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood 1997;90:2160-2170.
13. Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL: Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999;163:699-707.
14. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS: Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 1998;161:5607-5613.
15. Gong J, Chen L, Chen D, Kashiwaba M, Manome Y, Tanaka T, Kufe D: Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther 1997;4:1023-1028.
16. Dietz AB, Vuk-Pavlovic S: High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998;91:392-398.
17. Diebold SS, Kursa M, Wagner E, Cotten M, Zenke M: Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J Biol Chem 1999;274:19087-19094.
18. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E: Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028-1034.
19. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002;235:540-549.
20. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J: Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000;165:5713-5719.
21. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2001;166:2953-2960.
22. Zheng L, Huang XL, Fan Z, Borowski L, Wilson CC, Rinaldo CRJ: Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. AIDS Res Hum Retroviruses 1999;15:1011-1020.
23. Alijagic S, Moller P, Artuc M, Jurgovsky K, Czarnetzki BM, Schadendorf D: Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol 1995;25:3100-3107.
24. Pecher G, Spahn G, Schirrmann T, Kulbe H, Ziegner M, Schenk JA, Sandig V: Mucin (MUC1) gene transfer into human dendritic cells by cationic liposomes or recombinant adenovirus. Anticanc Res 2001;21:2591-2596.
25. Pecher G, Häring A, Kaiser L, Thiel E: Mucin gene (MUC1) transfected dendritic cells as vaccine - results from a phase I/II clinical trial. Cancer Immunol Immunother 2002;51:669-673.
26. Christ M, Lusky M, Stoeckel F, Dreyer D, Dieterle A, Michou AI, Pavirani A, Mehtali M: Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response. Immunol Lett 1997;57:19-25.
27. Nunes FA, Furth EE, Wilson JM, Raper SE: Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration. Hum Gene Ther 1999;10:2515-2526.
28. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA: DNA vaccines. Annu Rev Immunol 1997;15:617-648.
29. Ulmer JB, Donnelly JJ, Deck RR, DeWitt CM, Liu MA: Immunization against viral proteins with naked DNA. Ann N Y Acad Sci 1995;772:117-125.
30. Lekutis C, Shiver JW, Liu MA, Letvin NL: HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha. J Immunol 1997;158:4471-4477.
31. Wild J, Gruner B, Metzger K, Kuhrober A, Pudollek HP, Hauser H, Schirmbeck R, Reimann J: Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid. Vaccine 1998;16:353-360.
32. Etchart N, Buckland R, Liu MA, Wild TF, Kaiserlian D: Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 1997;78:1577-1580.
33. Martin T, Parker SE, Hedstrom R, Le T, Hoffman SL, Norman J, Hobart P, Lew D: Plasmid DNA malaria vaccine: The potential for genomic integration after intramuscular injection. Hum Gene Ther 1999;10:759-768.
34. Abe A, Emi N, Taji H, Kasai M, Kohno A, Saito H: Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy. Gene Ther 1996;3:988-993.
35. White SA, LoBuglio AF, Arani RB, Pike MJ, Moore SE, Barlow DL, Conry RM: Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine. J Gene Med 2000;2:135-140.
36. Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J: Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 1996;65:664-670.
37. Johnen H, Kulbe H, Pecher G: Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1) Cancer Immunol Immunother 2001;50:356-360.
38. Zhu D, Stevenson FK: DNA gene fusion vaccines against cancer. Curr Opin Mol Ther 2002;4:41-48.
39. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-1042.
40. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M: Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002;294:47-59.
41. Rice J, Elliott T, Buchan S, Stevenson FK: DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: Implications for cancer vaccines. J Immunol 2001;167:1558-1565.
42. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998;11:1281-1286.
43. Sedegah M, Weiss W, Sacci JB Jr, Charoenvit Y, Hedstrom R, Gowda K, Maja VF, Tine J, Kumar S, Hobart P, Hoffman SL: Improving protective immunity induced by DNA-based immunization: Priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 2000;164:5905-5912.
44. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW: Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-258.
45. Biragyn A, Kwak LW: B-cell malignancies as a model for cancer vaccines: From prototype protein to next generation genetic chemokine fusions. Immunol Rev 1999;170:115-126.
46. Krieg AM: Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med 1999;1:56-63.
47. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ.: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001;69:81-88.
48. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G: Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001;31:2154-2163.
49. Schirmbeck R, Reimann J: Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology 2001;44:115-123.
50. Walther W, Stein U, Fichtner I, Voss C, Schmidt T, Schleef M, Nellessen T, Schlag PM: Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol Biotechnol 2002;21:105-115.
51. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW: Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-683.
52. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY: Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000;6:24-33.
53. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW: Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-214.
54. Von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-1191.
55. Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H: Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 2002;20:1862-1869.
56. Zaloudik J, Li W, Jacob L, Kieny MP, Somasundaram R, Acres B, Song H, Zhang T, Li J, Herlyn D: Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther 2002;9:382-389.
57. Chen CH, Wang TL, Hung CF, Pardoll DM, Wu TC: Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000;18:2015-2022.
58. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP: Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated Antigen. J Immunol 1996;156:224-231.
59. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-1900.
60. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HAT: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 2000;38:208-217.